论文部分内容阅读
目的观察重组人角质细胞生长因子(rhKGF)异构体(K102)对实验性肝纤维化的预防和治疗作用。方法取90只Wistar大鼠,随机分为K102大剂量组(2.0mg/kg),K102小剂量组(0.5mg/kg)和模型对照组,用50%CCl4与精制花生油按1:1(v/v)比例混合,灌服大鼠,每周2次,同时K102大、小剂量组皮下注射相应剂量的K102,模型对照组皮下注射等量溶媒,分别连续用药6周和8周。另取36只大鼠,随机分为3组,复制肝纤维化模型后,再给予相应药物6周,同时设正常大鼠对照组(12只)。实验结束后处死各组动物,并采集血液和肝脏组织,检测肝功、肝组织羟脯氨酸含量,并进行肝脏病理和胶原特殊染色观察。结果 K102能明显改善大鼠的肝功,降低肝组织羟脯氨酸含量,与模型对照组比较,差异有统计学意义。肝脏病理观察显示,K102治疗组较模型对照组病变轻微;胶原特殊染色显示,K102治疗组中仅见少量胶原纤维。结论 K102对实验性肝纤维化有一定的预防和治疗作用,为临床研究提供了依据。
Objective To observe the preventive and therapeutic effects of recombinant human keratinocyte growth factor (K102) on experimental hepatic fibrosis. Methods Ninety Wistar rats were randomly divided into three groups: K102 high dose group (2.0mg / kg), K102 low dose group (0.5mg / kg) and model control group. The rats were treated with 50% / v), the rats were fed twice a week, while the K102, small dose group were injected subcutaneously with the corresponding dose of K102. The model control group was subcutaneously injected with the same amount of vehicle for 6 weeks and 8 weeks respectively. Another 36 rats were randomly divided into three groups. After the model of liver fibrosis was duplicated, the corresponding drugs were given for another 6 weeks, and the normal control group (12 rats). At the end of the experiment, all animals were sacrificed and blood and liver tissues were collected. Hydroxyproline content of liver function and liver tissue were detected, and liver pathology and collagen special staining were observed. Results K102 can significantly improve liver function and reduce hydroxyproline content in liver tissue, compared with the model control group, the difference was statistically significant. Liver pathology showed that the K102 treatment group than in the model control group lesions slightly; collagen staining, K102 treatment group, only a small amount of collagen fibers. Conclusion K102 has some preventive and therapeutic effects on experimental liver fibrosis, which provides the basis for clinical research.